I. Herrmann

A new targeting approach for breast cancer gene therapy using the heparanase promoter.

D. Curiel, P. Reynolds, T. Schöndorf, 2006, Cancer letters.

Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells.

D. Nettelbeck, D. Curiel, R. Desmond, 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

Evaluation of a selectively oncolytic adenovirus for local and systemic treatment of cervical cancer

D. Curiel, R. Desmond, A. Hemminki, 2004, International journal of cancer.

Combining high selectivity of replication via CXCR4 promoter with fiber chimerism for effective adenoviral oncolysis in breast cancer

A. Rivera, D. Curiel, D. Eckhoff, 2007, International journal of cancer.

In vivo cervical cancer growth inhibition by genetically engineered cytotoxic T cells

G. Bauerschmitz, P. Dall, D. Niederacher, 2004, Cancer Immunology, Immunotherapy.

Tissue-specific promoters active in CD44+CD24-/low breast cancer cells.

A. Ristimäki, P. Virkkunen, A. Hemminki, 2008, Cancer research.

an Additive Therapeutic Strategy for Gynaecological Tumours

P. Dall, D. Rein, M. Hampl, 2022 .